OOIR: Observatory of International Research

Papers

(The H4-Index of Molecular Neurodegeneration is 53. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Retraction Note: Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5– implications for dementia with lewy bodies	445
In Memoriam of John T. Trojanowski, MD, PhD 1946-2022	252
Mutations in PSEN1 predispose inflammation in an astrocyte model of familial Alzheimer’s disease through disrupted regulated intramembrane proteolysis	242
Molecular hallmarks of excitatory and inhibitory neuronal resilience to Alzheimer’s disease	236
Mis-localization of endogenous TDP-43 leads to ALS-like early-stage metabolic dysfunction and progressive motor deficits	232
LRRK2 kinase activity regulates Parkinson’s disease-relevant lipids at the lysosome	220
Emerging targets of α-synuclein spreading in α-synucleinopathies: a review of mechanistic pathways and interventions	209
Tau interactome and RNA binding proteins in neurodegenerative diseases	198
Regulation of the hippocampal translatome by Apoer2-ICD release	191
TREM2 dependent and independent functions of microglia in Alzheimer’s disease	177
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application	169
A genome-wide search for pleiotropy in more than 100,000 harmonized longitudinal cognitive domain scores	150
Microglia sensing of peripheral signals that bridge the brain and body	149
Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration	136
Inhibition of soluble epoxide hydrolase confers neuroprotection and restores microglial homeostasis in a tauopathy mouse model	116
Cerebrospinal fluid markers link to synaptic plasticity responses and Alzheimer’s disease genetic pathways	112
The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons	106
Circadian clocks, cognition, and Alzheimer’s disease: synaptic mechanisms, signaling effectors, and chronotherapeutics	98
Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	97
Cautions on utilizing plasma GFAP level as a biomarker for reactive astrocytes in neurodegenerative diseases	95
Astrocytic autophagy plasticity modulates Aβ clearance and cognitive function in Alzheimer’s disease	94
Recombinant cathepsins B and L promote α-synuclein clearance and restore lysosomal function in human and murine models with α-synuclein pathology	94
Multi-region brain transcriptomic analysis of amyotrophic lateral sclerosis reveals widespread RNA alterations and substantial cerebellum involvement	92
Immunotherapy against tau fragment diminishes AD pathology, improving synaptic function and cognition	91
The role of NURR1 in metabolic abnormalities of Parkinson’s disease	91

Single-cell peripheral immunoprofiling of Lewy body and Parkinson’s disease in a multi-site cohort	89
Correction: Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	89
The role of peripheral inflammatory insults in Alzheimer’s disease: a review and research roadmap	82
Human VCP mutant ALS/FTD microglia display immune and lysosomal phenotypes independently of GPNMB	79
Unravelling cell type-specific responses to Parkinson’s Disease at single cell resolution	79
In Memoriam of Edward H. Koo, MD 1954–2025	77
BAX activation in mouse retinal ganglion cells occurs in two temporally and mechanistically distinct steps	77
HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	77
APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants	75
Correction: Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	75
Alzheimer risk gene product Pyk2 suppresses tau phosphorylation and phenotypic effects of tauopathy	73
Repetitive transcranial magnetic stimulation alleviates motor impairment in Parkinson’s disease: association with peripheral inflammatory regulatory T-cells and SYT6	73
Autophagic impairment in sleep–wake circuitry is linked to sleep loss at the early stages of Alzheimer’s disease	66
Entering the era of precision medicine to treat amyotrophic lateral sclerosis	65
Combination therapy using GDNF and cell transplant in Parkinson’s disease	65
Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease	62
Clinical progression and genetic pathways in body-first and brain-first Parkinson’s disease	61
Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis	59
α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease	59
Correction: The major TMEM106B dementia risk allele affects TMEM106B protein levels, fibril formation, and myelin lipid homeostasis in the ageing human hippocampus	58
A perspective on Alzheimer’s disease: exploring the potential of terminal/paradoxical lucidity and psychedelics	57
ASO-mediated knock-down of GPNMB in mutant-GRN and in Grn-deficient peripheral myeloid cells disrupts lysosomal function and immune responses	57
Deficits in mitochondrial TCA cycle and OXPHOS precede rod photoreceptor degeneration during chronic HIF activation	57
TMEM106B aggregation in neurodegenerative diseases: linking genetics to function	56
Correction: HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	55
Dementia with lewy bodies patients with high tau levels display unique proteome profiles	53
Common features of neurodegenerative disease: exploring the brain-eye connection and beyond (part 2): the 2021 pre-symposium of the 15th international conference on Alzheimer’s and Parkinson’s disease	53
Using mass spectrometry to validate mouse models of tauopathy	53